AUPH Stock — Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. (AUPH)

Updated October 16, 2026.

AUPH is a Stock. Total return is 430.9% over the past 25.3 years, 464.7 points behind SPY at 895.6%.

Aurinia Pharmaceuticals is a biopharmaceutical company developing therapies for autoimmune diseases with high unmet medical needs. The company markets LUPKYNIS (voclosporin), an oral therapy for adult patients with active lupus nephritis, and is developing aritinercept, a dual inhibitor being studied for potential treatment of various autoimmune conditions. The company does not currently have an established distribution schedule.

AUPH performance versus SPY

Price and return data through 2026-10-16.

Total return is 430.9% over the past 25.3 years, 464.7 points behind SPY at 895.6%. Over the past year its total return — price change plus distributions reinvested — is 42.9%. Its deepest 1-year drawdown was 21.8%.

AUPH key facts

Asset type

Stock

Asset class

Equity

Inception date

07/16/2001

Distribution frequency

None

Last close

$16.51 (as of 2026-10-16)

Market cap

$2,196,674,784

Average volume

736075.0

Beta

1.611

Payout ratio

0.0%

P/E ratio

7.24

Forward P/E

11.8343

EPS

$2.28

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AUPH risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 21.8%.

Who may consider AUPH — and who may not

It is a weaker fit for investors who need monthly cash flow (AUPH does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AUPH

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions